Vendor, Pflugerville, TX
Fabrico Technology, Inc.
UEI YMAJVR21PC43, CAGE 4LH67
3 awards and $2,088,064 obligated between February 28, 2024 and September 9, 2025, 100% under full and open competition, against 1.3 offers on average where reported.
Industries
NAICS on the awards, by dollars.
| Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)NAICS 541715 | $2,088,064 |
How it wins
Awards by competition, set-aside and type.
| Full and Open Competition After Exclusion of Sources | 3 |
| Small Business Set Aside - Total | 3 |
| Definitive Contract | 2 |
| Purchase Order | 1 |
Awards
Every award in the window, by dollars obligated.
| Contract | Awarding office | Described as | Obligated |
|---|---|---|---|
| HT942525C0011Definitive Contract, March 12, 2025, Full and Open Competition After Exclusion of Sources, 1 offers | Army Med Res Acq ActivityDefense Health Agency | DHA STTR Phase II Proposal H2-0803, Titled "development of Antibody Treatment of MDR Eskape Pathogen, P. Aeruginosa.", Medical R&D Contract.NAICS 541715, PSC AN12 | $1,299,972 |
| W911SR23C0016Definitive Contract, May 20, 2024, Full and Open Competition After Exclusion of Sources, 1 offers | W6QK ACC-APGDepartment of the Army | The Development of Small Molecule Therapeutics Specifically Targeting Members of the Bunyavirus Order.NAICS 541715, PSC AN11 | $538,100 |
| HT942524P0041Purchase Order, February 28, 2024, Full and Open Competition After Exclusion of Sources, 2 offers | Army Med Res Acq ActivityDefense Health Agency | DHA STTR PH I Medical Research and Development Purchase Order from Proposal - H23C-001-0029 for "development of Antibody Treatment of MDR EsNAICS 541715, PSC AN11 | $249,992 |
- Places of performance
- Texas
- Product and service codes
- AN12 Health R&D Services; Health Care Services; Applied ResearchAN11 Health R&D Services; Health Care Services; Basic Research
- Transactions
- 9 across 3 awards